HC Wainwright Raises Virios Therapeutics (NASDAQ:VIRI) Price Target to $5.00

Virios Therapeutics (NASDAQ:VIRI) had its price target increased by HC Wainwright from $0.20 to $5.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the stock.

Separately, Maxim Group started coverage on shares of Virios Therapeutics in a report on Thursday, June 20th. They issued a “buy” rating and a $1.00 target price on the stock.

Virios Therapeutics Stock Performance

Shares of NASDAQ:VIRI traded up $0.02 during trading on Wednesday, hitting $0.16. 42,675,668 shares of the stock were exchanged, compared to its average volume of 1,048,375. The company has a market capitalization of $4.30 million, a price-to-earnings ratio of -0.57 and a beta of 1.58. The company’s fifty day simple moving average is $0.19 and its 200-day simple moving average is $0.28. Virios Therapeutics has a 1-year low of $0.13 and a 1-year high of $1.04.

Virios Therapeutics (NASDAQ:VIRI) last posted its earnings results on Thursday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. During the same quarter in the prior year, the firm posted ($0.08) earnings per share. On average, research analysts forecast that Virios Therapeutics will post -0.22 earnings per share for the current fiscal year.

About Virios Therapeutics

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.